Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Taiho Oncology, Inc.
S-1 is an oral fluoropyrimidine which combines tegafur (a 5-FU prodrug) with two classes of modulators which: * inhibit dihydropyrimidine dehydrogenase (DPD) and * block phosphorylation of 5-FU in gastrointestinal tissues. S-1 is designed to enhance the the clinical utility of an oral fluoropyrimidine while ameliorating the disadvantage of gastrointestinal toxicity. 5-Fu and cisplatin have been used as a standard treatment in gastric cancer and preliminary data indicate that S-1 plus cisplatin may result in superior tolerability and efficacy in advanced gastric cancer. S-1 is currently approved in Japan for treatment of gastric cancer and head and neck cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
